

Avita Medical Announces Comprehensive Participation at International Society of Burn Injuries' 17th Biennial Congress Showcasing ReCell® Technology

Northridge, CA and Cambridge, UK, 10 October 2014 — Avita Medical Ltd. (ASX: [AVH](#)), (OTCQX: [AVMXY](#)) a regenerative medicine company specializing in the treatment of wounds, scars, and skin defects, today announced that ReCell® will feature prominently during the scientific programme of the International Society for Burn Injuries' (ISBI) 17th Biennial Congress, in Sydney, Australia, October 12th to 16th. The Company will participate in all aspects of this important forum including keynote addresses, faculty panel representation, five accepted presentations, and a company booth in the exhibition hall.

The ReCell® Spray-on Skin® product is a single-use, autologous cell harvesting technology that is applicable for a wide variety of burns, plastic, reconstructive and cosmetic procedures. "We've made excellent progress recently with ReCell from positive clinical trial outcomes, to compassionate use examples, to vital product enhancements, and we look forward to playing a major role at the Congress," commented Timothy Rooney, Avita Medical's Interim Chief Executive Officer.

Positive clinical outcomes for ReCell Spray-on Skin will be featured in five accepted presentations by Dr. Matthias Aust (Germany), Dr. Mehmet Bozkurt (Turkey), Mr. Jonathan Dunne (UK), Dr. James H. Holmes (US), and Avita's Non-Executive Director and Australian of the Year 2005, Dr. Fiona Wood FRACS, AM. Additionally, Dr. Wood will be a keynote speaker, symposium co-chair and panellist. The Company will also be showcasing ReCell in the exhibit hall to promote its use and answer questions clinicians may have regarding the product's diverse range of applications.

"Attending this important international conference provides an excellent forum to increase the ReCell technology platform's profile with the burn care community. ReCell is a transformational technology. It is essential that Avita Medical continues to raise awareness around the clinical impact and commercial role ReCell can play across multiple applications to these core audiences. I want to thank our clinical collaborators for continuing to demonstrate the breadth and potential of ReCell, and congratulate Dr. Wood on being honoured with so many esteemed roles at the Congress. We are fortunate to have such fantastic advocates for ReCell," concluded Mr. Rooney.

ABOUT AVITA MEDICAL LIMITED

Avita Medical (<http://www.avitamedical.com>) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell® Spray-On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

FOR FURTHER INFORMATION:

Avita Medical Ltd.
Tim Rooney
Interim Chief Executive Officer/Chief Financial
Officer
Phone: + 1 (818) 827-1695
Email: trooney@avitamedical.com

Avita Medical Ltd.
Lou Panaccio
Chairman
Phone: +61 (0) 8 9474 7738
Email: lpanaccio@avitamedical.com